BMS Stumble in HCV Trial Could Prove Gilead's Gain
By Mari Serebrov
Friday, August 3, 2012
In the heat of the race for an interferon-free treatment for hepatitis C virus (HCV), Bristol-Myers Squibb Co. (BMS) stumbled over a serious safety issue in a Phase IIb trial of BMS-986094.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.